AAD 2026: Almirall Presents New Clinical and Real‑world Evidence Across Atopic Dermatitis, Psoriasis, Actinic Keratosis and Acne
Almirall S.A. a global biopharmaceutical company dedicated to medical dermatology, is presenting a broad range of clinical and real‑world data across its portfolio at the 2026 American Academy of Dermatology (AAD) Annual Meeting. The company’s presence includes more than 15 scientific posters, led by 9 lebrikizumab presentations in atopic dermatitis (AD), new analyses on tirbanibulin (AK), two on tildrakizumab from the POSITIVE study, and two sarecycline pooled Phase 3 evaluations in acne.
“Our goal is to bring meaningful, evidence‑based treatment options to people living with skin diseases. The breadth of data we are sharing at AAD 2026 – from long‑term results and real‑world evidence for lebrikizumab to clinically relevant AK endpoints with tirbanibulin – reflects our commitment to rigorous science, patient‑centred outcomes, and strong collaboration with dermatology partners,” said Dr. Volker Koscielny, Almirall’s Chief Medical Officer.
“AAD is an important moment each year to demonstrate our dedication to advancing medical dermatology and patient care. The new data we are sharing underline the real progress made across multiple skin diseases, and our commitment to bringing dermatologists evidence that supports better decision‑making and better care for their patients,” said Paul Rittman, President & General Manager, Almirall U.S.
Almirall’s presence at AAD 2026 is an important opportunity to connect with healthcare professionals, partners, and industry peers. AAD 2026 is a leading international forum for medical dermatology expertise and collaboration and takes place March 27–31 in Denver, Colorado.
Addressing Unmet Needs in Medical Dermatology
Dermatological diseases can exert a profound physical and emotional burden. With a portfolio spanning inflammatory and proliferative skin conditions and an expanding evidence base across both controlled and real‑world settings, Almirall continues to partner with the dermatology community to improve outcomes, experience and long‑term disease control.
With over 80 years of experience in healthcare, Almirall is committed to advancing science in dermatology through continuous investment in research and development and by fostering strong partnerships with the medical and scientific communities. The company’s expanding portfolio in medical dermatology, particularly its focus on advanced biologic solutions for psoriasis and atopic dermatitis, underscores its dedication to providing innovative dermatological treatments and enhancing patient outcomes.
2026 AAD Annual Meeting poster overview:
Almirall and its partners will present more than 15 scientific posters across atopic dermatitis, psoriasis, actinic keratosis and acne, including:
Lebrikizumab (Atopic Dermatitis) – 3 Almirall Posters + 6 Eli Lilly Posters
- Head, neck and face AD in patients with skin of color (ADmirable)
- 4 year long-term safety and efficacy (ADlong)
- Real-world effectiveness and advanced systemic pretreated populations (ADLIFE)
- Improvements in absolute endpoints in real-world settings (ADLIFE)
- EASI clinical responses across body regions in patients needing >16 weeks to reach EASI 75/IGA 0–1
- Clinical feature improvements in skin of color
- Allergic rhinitis comorbidity and PREPARED‑1 study design
- Reasons for initiating lebrikizumab in adolescents with moderate-to-severe AD
- Exposure–response modelling supporting every 8 week maintenance dosing
Tildrakizumab (Psoriasis) – 2 Almirall Posters + 4 Sun Pharma Posters
- Effectiveness of tildrakizumab in patients with moderate-to-severe psoriasis overall and in high-impact areas: 2-year results from the POSITIVE study
- Beyond skin clearance: Tildrakizumab in moderate-to-severe psoriasis patients – 2-year POSITIVE study results
- Efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis affecting the nails: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b trial
- Real-World Tildrakizumab Effectiveness in the US by Biologic Experience and Geographic Region in the PPD CorEvitas Psoriasis Registry
- Real-World Tildrakizumab Persistence in the US by Biologic Experience and Insurance Coverage in the PPD CorEvitas Psoriasis Registry
- Regional Differences in Patient Characteristics Among US Biologic Initiators from the PPD CorEvitas Psoriasis Registry
Tirbanibulin (Actinic Keratosis) – 3 Posters
- Efficacy beyond complete clearance: percent lesion reduction as a meaningful endpoint
- Efficacy, safety and tolerability of up to two 5-day treatment courses
- Achieving complete clearance with mild-to-moderate LSRs: pooled Phase III analysis
About Almirall
Almirall is a global biopharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose: to transform the patients’ world by helping them realize their hopes and dreams for a healthy life. We are at the forefront of science to deliver ground-breaking, differentiated medical dermatology innovations that address patients’ needs.
Source link: https://www.businesswire.com/
